BlackRock, Inc. Reports Decreased Ownership in Inhibrx Biosciences, Inc.

BlackRock, Inc. has filed an amendment to its Schedule 13G/A, reporting a decrease in its ownership of Inhibrx Biosciences, Inc. common stock. As of September 30, 2025, BlackRock owns 680,368 shares, representing 4.7% of the total outstanding shares. This marks a significant decrease from its previous holdings, with a value change of -$16,908,583,171.48 and a shares change of -14,561,803. The filing indicates that BlackRock acquired and holds these securities in the ordinary course of business and not for the purpose of influencing control of the issuer. The filing was signed by Spencer Fleming, Managing Director, on October 17, 2025.